Change in Opioid use and overdose after a medicaid lock-in program

描述(申请人提供)：处方阿片类药物滥用在美国是一种日益严重的公共卫生流行病，估计每年导致15,000人死亡，社会成本超过550亿美元。作为回应，各州正在越来越多地通过医疗补助锁定计划(MLIP)来管理CS滥用。北卡罗来纳州(北卡罗来纳州)接受者管理MLIP于2010年10月启动，旨在减少阿片类药物和抗焦虑药的欺诈性处方报销，同时改善需要积极疼痛管理的患者的治疗连续性。该计划将符合条件的患者限制在一家供应商和一家药房，为期12个月。到目前为止，识别适合NC和其他MLIP的患者的算法主要基于州医疗补助人员的最佳临床判断。除了MLIP，NC还实施了受控物质报告系统(CSRS)，该系统监测CS的所有处方，无论付款人类型如何。结合NC MLIP和CSRS的数据创造了一个独特的机会：(1)评估NC MLIP的实施情况，以及(2)检查NC MLIP中个人填写的CS处方的变化，而不考虑保险公司。因此，我们建议在目前的NC MLIP中检查利用率和过量结果。具体目标#1，将使用与主要利益相关者--计划管理员、医生和药剂师--的访谈来执行过程评估，以确定NC MLIP的运行环境。特定目标#2和#3将使用医疗补助索赔数据和CSRS来检查NC MLIP对CS处方者和处方者数量的影响，而特定目标#4将检查NC MLIP对CS过量的影响。北卡罗来纳州的MLIP将继续由许多州开发和实施。对NC MLIP的严格评估对于建立制定有效政策的基础至关重要，这些政策可以减少美国处方药滥用的破坏性后果。拟议的研究将利用一个独特和强大的数据库来审查NC MLIP对CS使用和滥用的影响。这项研究的结果有可能极大地减少CS虐待在人的生命和财政资源方面的成本。

DESCRIPTION (provided by applicant): Prescription opioid abuse is a growing public health epidemic in the US, contributing to an estimated 15,000 deaths and more than $55 billion in societal costs per year. In response, states are increasingly managing CS abuse with Medicaid Lock in Programs (MLIP). The North Carolina (NC) Recipient Management MLIP, initiated in October of 2010, was designed to reduce fraudulent prescription claims for opioids and anxiolytics, while improving continuity of treatment among patients needing aggressive pain management. The program limits eligible patients to a single provider and a single pharmacy for a 12 month period. To date, algorithms to identify patients appropriate for the NC and other MLIPs have been based primarily on the best clinical judgment of state Medicaid personnel. Separate from the MLIP, NC also implemented the Controlled Substances Reporting System (CSRS), which monitors all prescriptions for CS, regardless of payer type. Combining data from the NC MLIP and the CSRS creates a unique opportunity to: (1) assess the implementation of the NC MLIP and (2) examine changes in CS prescriptions filled among individuals in the NC MLIP, regardless of insurer. Therefore, we propose to examine utilization and overdose outcomes in the current NC MLIP. Specific Aim #1, will use interviews with key stakeholders-program administrators, physicians, and pharmacists-to perform a process assessment in order to determine the context in which the NC MLIP operates. Specific Aims #2 and #3 will use Medicaid claims data and the CSRS to examine the effect of the NC MLIP on the number of CS prescription and prescribers, while Specific Aim #4 examines the effect of the NC MLIP on CS overdose. MLIPs such as the one in NC will continue to be developed and implemented by many states. A rigorous evaluation of the NC MLIP is critical to building the foundation for developing effective policies that can reduce the devastating consequences of prescription drug abuse in the US. The proposed study will capitalize on a unique and powerful database to examine the effect of the NC MLIP on CS use and abuse. The results of this study have the potential to substantially reduce the cost of CS abuse in terms of human lives and financial resources.